Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 9170-9177
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.9170
Table 3 Summary of factors associated with dose intensification in the multivariate analysis
| Factor | Adjusted Hazard ratio | 95%CI | P value |
| Corticosteroid dependence (yes/no) | 1.359 | 0.425-4.343 | 0.605 |
| Age | 1.015 | 0.991-1.040 | 0.216 |
| Induction with corticosteroids (yes/no) | 1.258 | 0.521-3.041 | 0.610 |
| 0Immunomodulator use (yes/no) | 0.510 | 0.242-1.073 | 0.076 |
| Disease (ulcerative colitis vs Crohn´s disease) | 2.732 | 1.313-5.686 | 0.007 |
- Citation: Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177
- URL: https://www.wjgnet.com/1007-9327/full/v20/i27/9170.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i27.9170